Q&A published 14 March 2011 [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2011-03-16 14:44 (4346 d 07:31 ago) – Posting: # 6762
Views: 32,510

Dear all,

the clarification is part of the recent version of the “Questions & Answers: Positions on specific questions addressed to the Pharmacokinetics Working Party” EMA/618604/2000 Rev. 3, dated 26 January 2011, published 14 March 2011.
The interesting part is Section 11. Clarification on the recommended statistical method for the analysis of a bioequivalence study (pages 21–32).

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
22 visitors (0 registered, 22 guests [including 7 identified bots]).
Forum time: 22:16 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz